Mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK) and c‐ros oncogene 1 (ROS1) have emerged as effective therapeutic targets for advanced lung adenocarcinoma.4 The gene discussed is ALK; the disease is lung adenocarcinoma.